Retatrutide is a peptide-based drug that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. It is used in the treatment of type 2 diabetes mellitus to help regulate blood sugar levels. Retatrutide works by stimulating the GLP-1 receptors in the pancreas, which leads to increased insulin secretion and decreased glucagon secretion. This helps to lower blood sugar levels and improve glycemic control in patients with diabetes.
Retatrutide is a triple agonist peptide drug candidate targeting GLP-1, GIP, and glucagon receptors. It is synthesized via solid-phase peptide synthesis (SPPS) for clinical obesity and metabolic disorder treatments. Molecular Formula: C207H324N62O59. CAS No.: 2285777-43-5.
Strictly for research use only; not approved for commercial sale in most jurisdictions. Store at -20°C under inert atmosphere to maintain stability. Handle with appropriate PPE due to potential biological activity and sensitization risks.